|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplemental Table 3: Age as a continuous variable.** Multivariable\* adjusted hazard ratio (HR) and 95% confidence interval (CI) estimates for overall survival and Hodgkin lymphoma-specific survival in children and adolescent/young adult patients with classical HL, by age group, California, 2007- 2017. **Significant HRs are in bold.** | | | | |
|  | **Ages ≤21 years** | | **Ages 22–39 years** | |
|  | **OS**  **HR (95% CI)** | **DSS**  **HR (95% CI)** | **OS**  **HR (95% CI)** | **DSS**  **HR (95% CI)** |
| **Age** | | | | |
| Continuous | **1.12 (1.02, 1.24)** | **1.19 (1.03, 1.38)** | **1.04 (1.01, 1.07)** | 1.02 (0.98, 1.06) |
| **Sex (R: Male)** | | | | |  |  |  |  |
| Female | 0.80 (0.47, 1.36) | 0.64 (0.32, 1.29) | 0.89 (0.65, 1.22) | 0.98 (0.65, 1.47) |
| **Race/ethnicity (R: NH White)** | | | | |  |  |  |  |
| Hispanic | 1.73 (0.86, 3.45) | 2.09 (0.82, 5.33) | 1.31 (0.91, 1.88) | 1.37 (0.86, 2.18) |
| NH Black | **3.22 (1.41, 7.32)** | **5.75 (1.98, 16.69)** | 1.60 (0.97, 2.63) | 1.20 (0.59, 2.42) |
| NH Asian/PI | 1.16 (0.44, 3.05) | 1.81 (0.53, 6.23) | 1.18 (0.69, 2.01) | 0.95 (0.47, 1.89) |
| **Health insurance (R: private)** | | | | |
| Public/none | **1.91 (1.07, 3.40**) | 1.27 (0.59, 2.74) | **1.79 (1.29, 2.49)** | **1.62 (1.05, 2.50)** |
| Unknown | 3.08 (0.85, 11.13) | **4.97 (1.28, 19.25)** | 1.95 (0.87, 4.34) | 2.57 (0.99, 6.62) |
| **Neighborhood SES (R: high)** | | | | |
| Low SES | 1.04 (0.50, 2.17) | 1.39 (0.53, 3.63) | 0.90 (0.59, 1.38) | 0.71 (0.40, 1.25) |
| Middle SES | 0.96 (0.48, 1.93) | 1.33 (0.53, 3.38) | 1.15 (0.79, 1.67) | 1.12 (0.70, 1.78) |
| **Stage at diagnosis (R: I)** |  |  |  |  |
| Stage II | 0.99 (0.28, 3.41) | 1.84 (0.23, 14.84) | 1.44 (0.67, 3.09) | 1.46 (0.51, 4.19) |
| Stage III | 0.74 (0.19, 2.86) | 1.32 (0.14, 12.07) | **2.47 (1.13, 5.40)** | 2.03 (0.68, 6.09) |
| Stage IV | 1.62 (0.45, 5.82) | 2.81 (0.34, 23.22) | **2.37 (1.08, 5.18)** | 2.56 (0.87, 7.54) |
| **B-symptoms (R: No)** |  |  |  |  |
| Yes | 1.47 (0.79, 2.72) | 1.14 (0.52, 2.50) | **2.64 (1.79, 3.91)** | **2.83 (1.69, 4.71)** |
| Unknown | 1.59 (0.49, 5.16) | 1.21 (0.23, 6.46) | 1.63 (0.83, 3.21) | **2.55 (1.07, 6.08)** |
| **Histology (R: NS)** | | | | |
| Classical HL, NOS | 1.34 (0.71, 2.52) | 1.10 (0.46, 2.61) | **1.85 (1.33, 2.58)** | **1.73 (1.11, 2.68)** |
| Mixed cellularity | 0.51 (0.15, 1.77) | 0.80 (0.17, 3.67) | 1.03 (0.60, 1.78) | 0.93 (0.44, 1.99) |
| **Chemotherapy regimen (R: ABVD)** | | | | |
| ABVE-PC | 0.94 (0.24, 3.65) | 0.44 (0.05, 4.17) |  |  |
| BEACOPP | 0.30 (0.04, 2.27) | 0.56 (0.07, 4.46) | **2.63 (1.05, 6.62)** | **3.58 (1.38, 9.28)** |
| Stanford V | 2.12 (0.71, 6.35) | 1.27 (0.25, 6.39) | 0.83 (0.33, 2.11) | 0.34 (0.08, 1.42) |
| Modified regimens | 1.08 (0.50, 2.31) | 0.86 (0.31, 2.40) | **2.16 (1.39, 3.37)** | 1.67 (0.89, 3.13) |
| No/unknown chemo treatment | 0.35 (0.04, 2.86) | 0.44 (0.05, 4.38) | **1.90 (1.04, 3.46)** | 0.58 (0.17, 2.00) |
| Chemo, NOS | 3.10 (0.67, 14.22) |  | 1.95 (0.87, 4.36) | 0.87 (0.20, 3.73) |
| **Radiation therapy (R: Yes)** | | | | |
| No/unknown | 1.14 (0.64, 2.05) | 0.95 (0.44, 2.01) | 1.03 (0.69, 1.53) | 0.68 (0.43, 1.09) |
| **Hematopoietic cell transplantation (R: No)** | | | | |
| Yes | **8.30 (4.43, 15.54)** | **7.69 (3.40, 17.38)** | **7.59 (5.23, 11.02)** | **8.70 (5.57, 13.59)** |
| \*Models adjusted for all variables in the table. *Abbreviations:* R: reference group; NH: non-Hispanic; SES: socioeconomic status; NOS: not-otherwise specified; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine ABVE-PC: doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone Stanford V: doxorubicin, vinblastine, nitrogen mustard, etoposide, vincristine, bleomycin, prednisone | | | | |